Management of recurrent ovarian cancer: Evidence-based decisions

Current Opinion in Oncology

Volumn 14, Issue 5, 2002, Pages 519-527

  Salom, Emery ^a   Almeida, Zoyla ^a   Mirhashemi, Ramin ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTRETAMINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; NAVELBINE; PACLITAXEL; TAMOXIFEN; TOPOTECAN;

ANEMIA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; FEMALE; HOT FLUSH; HUMAN; MUCOSA INFLAMMATION; NEUTROPENIA; OVARY CANCER; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; SALVAGE THERAPY; SECOND LOOK SURGERY; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CLINICAL TRIALS; CYTOKINES; DECISION MAKING; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; IMMUNOTHERAPY; LAPAROTOMY; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PROGNOSIS; QUALITY OF LIFE; SALVAGE THERAPY; SECOND-LOOK SURGERY;

EID: 0036738232     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200209000-00008     Document Type: Review

References (34)

1. Scarabelli C, Gallo A, Fancheschi S, et al.: Primary cytoreductive surgery with recto sigmoid colon resection for patients with advanced epithelial ovarian cancer. Cancer 2000, 88:389-397.
2. McGuire W, Hoskins J, Brady FB, et al.: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage II and stage IV ovarian cancer. N Engl J Med 1996, 334:1-6.
3. Mundarah A, Levenback C, Wolf J, et al.: Secondary cytoreductive surgery for intra-abdominal recurrences in epithelial ovarian cancer. Gynecol Oncol 2001, 81:237-241.
4. Berek JS, Hacker NF, Lagasse LD, et al.: Survival of patients following secondary cytoreductive surgery in ovarian cancer. Obstet Gynecol 1983, 61:189-193.
5. Vaccarello L, Rubin SC, Vlamis V, et al.: Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response. Gynecol Oncol 1995, 57:61-65.
6. Segna RA, Dottino PR, Mandeli JP, et al.: Secondary cytoreduction for ovarian cancer following cisplatin therapy. J Clin Oncol 1993, 11:434-439.
7. Kuhn W, Schmalfeldt B, Pache L, et al.: Disease-adapted relapse therapy for ovarian cancer: results of a prospective study. Int J Oncol 1998, 13:57-63.
8. Gore ME, Fryatt I, Wiltshaw E, et al.: Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 1990, 36:207-211.
9. Gronlund B, Hogdall C, Hansen H, et al.: Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer. Gynecol Oncol 2001, 83:128-134.
10. Rose PG, Fusco N, Fluellen L, et al.: Second-line therapy with paclitaxel carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J Clin Oncol 1998, 16:1494-1497.
11. Zanotti KM, Belinson JL, Kennedy AW, et al.: Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy. Gynecol Oncol 2000, 79:211-215.
12. McGuire WP, Blessing JA, Bookman MA, et al.: Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2000, 18:1062-1067.
13. Gore M, Rustin G, Schuller J, et al.: Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer. Br J Cancer 2001, 84:1043-1046.
14. Markman M, Blessing JA, Alverez RD, et al.: Phase II evaluation of 24-hour continuous infusion of topotecan in recurrent, potentially platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 1999, 77:112-115.
15. Clarke-Pearson D, Van Le L, Iveson T, et al.: Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer. J Clin Oncol 2001, 19:3967-3975.
16. Du Bois A, Luck H, Pfisterer J, et al.: Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer: a dose-finding study by the Arbeitsgemeinschaft Gynakologische Onkologie (AGO) Ovarian Cancer Study Group. Ann Oncol 2001, 12:1115-1120.
17. Ishikawa H, Nakanishi T, Nawa A, et al.: 3-Hour infusion of single-agent paclitaxel for recurrent ovarian cancer. Int J Clin Oncol 2001, 6:128-131.
18. Rodriguez M, Rose P: Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer. Gynecol Oncol 2001, 83:257-262.
19. Muggia FM, Hainsworth JD, Jeffers S, et al.: Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997, 15:987-993.
20. Campos S, Penson R, Mays A, et al.: The clinical utility of liposomal doxorubicin in recurrent ovarian cancer. Gynecol Oncol 2001, 81:206-212.
21. Rose P, Maxson J, Fusco N: Liposomal doxorubicin in ovarian peritoneal and tubal carcinoma: a retrospective comparative study of single agent dosages. Gynecol Oncol 2001, 82:323-328.
22. Gordon A, Fleagle J, Gunthrie D, et al.: Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001, 19:3312-3322.
23. Rose PG, Blessing JA, Mayer AR, et al.: Prolonged oral etoposide as a second-line therapy for platinum resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1998, 16:405-410.
24. Siff PJ, Bayer R, Kerger C, et al.: High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: A multivariate analysis of survival for 100 consecutively treated patients. J Clin Oncol 1997, 15:1309-1317.
25. Lederman JA, Herd R, Maraninchi D, et al.: High-dose chemotherapy for ovarian carcinoma: long-term results from the solid tumor registry of the European Group for Blood and Marrow Transplantation (EBMT). 2001, 12:693-699.
26. Molthoff CF, Prinssen HM, Kenemans P, et al.: Escalating protein doses of chimeric monoclonal antibody Mov18 immunoglobulin G in ovarian carcinoma patients: a phase I study. Cancer 1997, 80(suppl 12):2712-2720.
27. Schmolling J, Reinsberg J, Wagner U, et al.: Anti-TAG-72 antibody B72.3-immunologic and clinical effects in ovarian carcinoma. Hybridoma 1997, 16:53-58.
28. Canevari S, Stoter G, Arienti F, et al.: Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibodies. J Natl Cancer Inst 1995, 87:1463-1469.
29. Berek JS, Stonebraker B, Lentz SS, et al.: Intraperitoneal alpha-interferon in residual ovarian carcinoma: a phase II Gynecologic Oncology Group study [abstract]. Proc ASCO 1998, 17:353a.
30. Weisenthal LM, Dern KH: Highly specific prediction of antineoplastic drug resistance with an in-vitro assay using suprapharmacologic drug exposures. J Natl Cancer Inst 1990, 82:582-588.
31. Csoka K, Tholander B, Gerdin E, et al.: In-vitro determination of cytotoxic drug response in ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer 1997, 72:1008-1012.
32. Andreotti P, Cree IA, Kurbacher CM, et al.: Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 1995, 55:8276-8282.
33. Mehta R, Parker R, Fruehauf J, et al.: Ovarian cancer patients with in vitro resistance to platinum exhibit poorer survival after treatment with platinum based chemotherapy [abstract]. Proc Am Assoc Cancer Res 2000:5468.
34. Orr JW, Kern D: Cost effective treatment of women with advanced ovarian caner by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance. Cancer J Sci Am 1999, 5:174-178.